RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $29 to $36.
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $29 to $36.